How Nestlé is using next-gen tech to target GLP-1 consumers

Nestlé factory.
Nestlé targets GLP-1 users with new products. (Source: Reuters)
Nestlé is seeking to turn the rise of GLP-1 weight-loss drugs from a threat into a business opportunity, using artificial intelligence and nutritional science to develop products aimed at millions of consumers taking medicines such as Ozempic and Wegovy. The rapid adoption of drugs made by Novo Nordisk and Eli Lilly has fueled investor concerns that appetite-suppressing medicines could permanently reduce demand for packaged foods, snacks and beverages. Nestlé believes the drugs are also creati

This content is for IR Pro subscribers only.

Subscribe now to unlock an all-access pass.

IR Pro - Monthly

$4 for the first 30 days. (Auto renews at $20 per month.)
  • Unlimited news access
  • Daily IR Pro content straight to your inbox
  • Exclusive members only masterclasses (live and on-demand)
  • Weekly careers advice
  • Independent research reports and forecasts
  • Indepth interviews with industry leaders and experts
  • Weekly and quarterly digital magazines delivered to your inbox
Subscribe now
Retailer’s choice

IR Pro - Annual

$199 per year. (Auto renews annually.)
  • Unlimited news access
  • Daily IR Pro content straight to your inbox
  • Exclusive members only masterclasses (live and on-demand)
  • Weekly careers advice
  • Independent research reports and forecasts
  • Indepth interviews with industry leaders and experts
  • Weekly and quarterly digital magazines delivered to your inbox
Subscribe now

Recommended By IR